---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-220656"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2026-05-13T12:08:41+00:00"
generated_at: "2026-05-13T12:11:58.362794+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Therapeutics raises $87.5M in PIPE, extends cash runway into H2 2028

## Summary
- Sells 4.33M shares at $3.92/share and 17.99M pre-funded warrants at $3.9199/warrant.
- PIPE includes existing investors Avoro Capital, QVT, Coastlands, KVP, ADAR1, Acuta, StemPoint, Invus, and executives.
- Expected close May 14, 2026; net proceeds for working capital and ADC pipeline advancement.
- Cash runway extended into second half of 2028.
- Lock-up agreements for executives/directors: 60 days post-closing.

## SEC filing metadata
- accession: 0001193125-26-220656
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2026-05-13T12:08:41+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312526220656/0001193125-26-220656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312526220656/d854431d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-220656
- JSON: https://secwatch.observer/filing/0001193125-26-220656.json
- Plain text: https://secwatch.observer/filing/0001193125-26-220656.txt

## Key facts
- Material Agreements
  Whitehawk Therapeutics, Inc. entered into Securities Purchase Agreement with each of the purchasers named therein (the "PIPE Investors") valued at $87,500,000 (effective 2026-05-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: each of the purchasers named therein (the "PIPE Investors")
  - Value: $87,500,000
  - Effective: 2026-05-12
  source text: On May 12, 2026, Whitehawk Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers named therein (the “PIPE Investors”), pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $3.92 per share, and (ii) 17,991,021 pre-funded warrants to acquire Common Stock (the “Pre-Funded Warrants”), at a purchase price of $3.9199 per Pre-Funded Warrant, for an aggregate purchase price of $87,500,000 (collectively, the “PIPE Financing”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312526220656/0001193125-26-220656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.